Hope for kids with rare, relapsed cancers: experimental drug trial opens access
NCT ID NCT03581240
Summary
This trial provides expanded access to an experimental drug called DFMO for children and young adults (ages 0-30) with rare, relapsed cancers like neuroblastoma and medulloblastoma. The goal is to see if DFMO can help control these aggressive cancers after standard treatments have failed. Participants must have completed standard therapies and have specific genetic features in their tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDULLOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Penn State Milton S. Hershey Medical Center and Children's Hospital
AVAILABLEHershey, Pennsylvania, 17033, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.